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Abstract: Mesenchymal stromal cells (MSCs) are adult 
progenitor cells with a high migratory and differentiation 
potential, which influence a broad range of biological 
functions in almost every tissue of the body. Among other 
mechanisms, MSCs do so by the secretion of molecular 
cues, differentiation toward more specialized cell types, or 
influence on the immune system. Expanding tumors also 
depend on the contribution of MSCs to building a support-
ing stroma, but the effects of MSCs appear to go beyond 
the mere supply of connective tissues. MSCs show targeted 
“homing” toward growing tumors, which is then followed 
by exerting direct and indirect effects on cancer cells. 
Several research groups have developed novel strategies 
that make use of the tumor tropism of MSCs by engineer-
ing them to express a transgene that enables an attack on 
cancer growth. This review aims to familiarize the reader 
with the current knowledge about MSC biology, the exist-
ing evidence for MSC contribution to tumor growth with its 
underlying mechanisms, and the strategies that have been 
developed using MSCs to deploy an anticancer therapy.
Keywords: HSV-Tk; mesenchymal stromal cells; MSC; 
suicide gene therapy; tumor stroma.
Introduction
Mesenchymal stem/stromal cells (MSCs) represent a pop-
ulation of precursor cells with high differentiation poten-
tial, which can be isolated and expanded easily in large 
amounts from adult mammals without ethical conflicts. 
The main source of these cells is the bone marrow, but their 
presence has been demonstrated in several other tissues. 
Recent studies, which underline the immune privilege, 
plasticity, and migratory potential of these cells, have 
made them ideal candidate cells for applications touch-
ing the clinical field of surgical oncology. The plasticity 
of MSCs toward specialized cells of mesenchymal tissue 
(i.e. chondrocytes, adipocytes, and osteoblasts) strongly 
suggests the utilization of these cells in regenerative med-
icine. This continues to be one of the main fields of MSC 
research and potential clinical application of these cells 
but goes beyond the scope of this review. Yet, the aspects 
of high differentiation and migration capacity also made 
these cells noteworthy for cancer research. There is now 
a large body of evidence supporting the concept of MSCs 
representing a major precursor population for cells con-
tributing to tumor-associated stromal components. Within 
the tumor microenvironment, MSCs have been shown to 
give rise to tumor-associated fibroblasts (TAF), pericytes, 
endothelial cells, and fibrovascular stroma. The role of the 
tumor-supporting stroma concerning different important 
aspects of malignant tumor growth (i.e. invasion, metasta-
sization, chemoresistance, and radioresistance) remains 
controversially discussed, just as the contribution of 
MSCs to these processes is. However, irrespective of the 
potential protumorigenic or antitumorigenic effects that 
the natural biology of these cells may convey, the utiliza-
tion of MSCs as delivery vehicles for anticancer therapies 
of different kinds has been an emerging concept pursued 
by several research groups, including ours. The aim of 
this present review is to familiarize the reader with the 
current knowledge about general MSC biology (focusing 
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on aspects important for the clinical application of these 
cells), their involvement in tumor growth, and their use as 
delivery vehicles for cancer therapy.
Biology of MSCs
Characterization and sources of MSCs
MSCs were first described by Friedenstein et  al. as non-
hematopoietic stromal cells of the bone marrow capable 
of bone formation and termed as colony-forming-units-
fibroblasts (CFU-Fs) [1]. Caplan used the term “mesenchy-
mal stem cell” after his group discovered that CFU-Fs are 
possibly capable of self-renewal and differentiation [2]. 
The report from Pittenger et al. on the multilineage differ-
entiation potential of MSCs prompted further interest of 
the research community in these cells [3]. In the last two 
decades, the number of published studies dealing with 
MSCs has increased exponentially.
At the same time, protocols for the isolation and 
expansion of MSCs, and along with this the cell types 
described within these studies, began to vary markedly. 
Thus, the term “MSCs” in research articles may subsume 
several different types of more or less specialized stem 
or even progenitor cells. Currently, not a single cellular 
marker or receptor has been described to be unique to 
MSCs. Thus, to harmonize reports on MSC studies, the 
International Society for Cellular Therapy issued a posi-
tion statement with the minimum requirements for iso-
lated cell lines to classify as MSCs [4]. The prerequisites 
for such a cell line are as follows: (1) it must grow adherent 
to plastic in a cell culture flask; (2) it must express CD105, 
CD73, and CD90 and lack the expression of CD45, CD34, 
CD14 or CD11b, CD79α, or CD19 and HLA-DR; and (3) it 
must be capable to give rise to adipocytes, chondrocytes, 
and osteoblasts when put under specific culture condi-
tions in vitro. However, the plasticity of MSCs does not 
seem to end with these three cell types. There have been 
reports showing the differentiation of MSCs to epithelial 
cells and neurons (i.e. cells of ectodermal origin) and to 
muscle cells, gut epithelial cells, and lung cells (i.e. cells 
of endodermal origin) [5].
Researchers have been able to isolate cells with 
MSC characteristics from a variety of tissues, including 
bone marrow, adipose tissue [6], umbilical cord blood 
[7], Wharton’s jelly [8], skeletal muscle [9], periosteum 
[10], liver, brain, spleen, kidney, lung, thymus, and pan-
creas [11]. The distribution pattern of MSCs in virtually 
all postnatal organs have led to the theory that MSCs 
reside in the perivascular niche and should thus be 
termed “multipotent perivascular-derived cells” [12]. In 
fact, research results indicate that perivascular cells may 
account for a majority of tissue-resident MSCs. Pericytes 
isolated from several adult organs by combination of the 
surface markers NG2, CD146, and PDGFRβ showed the 
MSC characteristics of trilineage differentiation in vitro 
and osteoblast differentiation in vivo [13]. However, not 
the entire population of pericytes shows MSC charac-
teristics and MSCs have been shown to be the progeny 
of cells other than perivascular (such as glial cells, for 
example) [14, 15].
Physiological functions of MSCs
The physiological function of endogenous MSCs has been 
studied most intensely in the bone marrow, which repre-
sents the main source of MSCs. Here, MSCs are important 
for the construction and maintenance of the hematopoietic 
stem cell (HSC) niche [16]. MSCs do so by the expression 
of the “HSC maintenance factors” CXCL-12, c-kit ligand, 
angiopoietin-1, interleukin (IL)-7, vascular cell adhesion 
molecule-1, and osteopontin [17]. An important function of 
MSCs in this context seems to be the inhibition of inappro-
priate HSC differentiation, which is achieved by an immu-
nosuppressive phenotype of MSCs [18]. The perivascular 
localization of MSCs is believed to enable these cells to 
detect local or distant tissue damage and respond to such 
by directed migration and participation in the healing 
process. This hypothesis has been supported by studies 
from Seppanen et al. in a fetal microchimerism model in 
mice. Here, labeled fetal MSCs colonized the bone marrow 
of the mother. After the infliction of skin wounds to the 
mother postpartum, these cells showed migration toward 
these wounds and differentiated into a collagen-produc-
ing fibroblast-like cell [19]. Furthermore, the homing of 
MSCs to sites of inflammation is not only a trait observed 
in endogenous MSCs after being released from the bone 
marrow but can also be seen after the systemic injection 
of exogenous MSCs. In a skin wound model in an immu-
nocompromised mouse, human MSCs showed targeted 
tropism to the wound 3 days after injection and remained 
there for the duration of the experiment [20].
Immunological properties of MSCs
MSCs are hypothesized to be poorly immunogenic due 
to their low expression level of major histocompatibility 
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complex (MHC) I, lack of MHC II expression, and lack of 
expression of the costimulatory ligands CD40, CD80, and 
CD86 [21]. By this, MSCs have shown to avoid the recog-
nition of circulating T cells [22]. Thus, allogeneic trans-
plantation of MSCs is believed to involve a reduced risk of 
transplant rejection, giving rise to the idea of an allogeneic 
MSC preparation to be a “one-size-fits all, off-the-shelf” 
therapy [12]. However, data from experimental and clini-
cal studies prompted evidence that the transplantation 
of allogeneic MSCs may nonetheless provoke an immune 
response that leads to MSC rejection. Zangi et  al. exam-
ined the persistence of labeled MSCs and fibroblasts in a 
host mouse after injection and compared an allogeneic 
to a syngeneic transplantation setting [23]. The authors 
reported that syngeneic MSCs as well as fibroblasts sur-
vived in the host for the duration of the experiment (40 
days). In the allogeneic setting, however, fibroblasts and 
MSCs vanished by days 10 and 20 after injection, respec-
tively. Although the prolonged survival of MSCs versus 
fibroblasts observed in the latter experiment indicate the 
immunoevasiveness of MSCs, the fact that they did not 
survive as long as syngeneic MSCs supports the hypothe-
sis of a rejection after transplantation. This is further sup-
ported by the findings that, in mice previously injected 
with allo-MSCs, the rejection of fibroblasts from the same 
donor was accelerated to day 2 after injection and these 
mice harbored an elevated memory T-cell count. The 
immunogenic properties of allogeneic MSCs after trans-
plantation can be explained by the findings that the low to 
nonexistent MHC expression levels in naïve MSCs become 
elevated after exposure to interferon (IFN)-γ or differen-
tiation into mature cells [24]. Data from a clinical study 
also point toward allogeneic MSCs being immunogenic 
with a high potential of being rejected after transplanta-
tion. An autopsy study on patients who died within a year 
after transplantation of MHC-mismatched or haploidenti-
cal MSCs revealed that donor DNA was only observable 
in peripheral tissues of only 1 of the 18 patients studied. 
This single patient received the allo-MSC infusion just 
7 days before his death and while being severely immuno-
compromised due to severe sepsis [25]. In all the other 17 
patients, the transplanted allo-MSCs appear to have fallen 
victim to rejection.
On the contrary, MSCs have a high capacity of modu-
lating the response of both innate and adaptive immune 
systems by differentially influencing the proliferation of 
immune cells. The main mechanism for this is believed to 
lie in the capacity of MSCs to secrete anti-inflammatory 
mediators and inhibitory molecules such as transform-
ing growth factor-β (TGF-β), hepatocyte growth factor 
(HGF), prostaglandin E2 (PGE2), PD-L1, and FasL [26–29]. 
MSCs inhibit the proliferation and maturation of B cells 
and natural killer (NK) cells while showing protective 
activities toward neutrophils [30, 31]. Furthermore, MSCs 
have been shown to inhibit the proliferation of CD4+ and 
CD8+ T cells [32] and may also promote the induction of 
regulatory T and B cells as well as anti-inflammatory mac-
rophages [33, 34]. The clinical effect of this MSC-mediated 
immunosuppression is observable in the prolonged sur-
vival of MHC-mismatched skin grafts in baboons achieved 
by an intravenous injection of MSCs immediately before 
transplantation [35]. The immunosuppressive effects of 
MSCs are so profound that they have been successfully 
used in patients to ameliorate graft-versus-host disease 
(GVHD) [36].
These properties of MSCs as well as others have 
yielded a high interest of the scientific community in a 
potential clinical use of these cells.
MSCs in cancer biology
Tumor stroma as a hallmark of cancer
In an attempt to condense the complexity of cancer 
biology, Hanahan and Weinberg identified several traits 
that appear mandatory for cancer cells to develop the full 
clinical picture of the disease and that describe the general 
phenomenon shared by several cancer entities. These 
“hallmarks of cancer” include cellular self-sufficiency 
in growth signals, insensitivity to antigrowth signals, 
evasion of cell death programs, and limitless replicative 
potential as well as tumor angiogenesis, tissue invasion 
and metastasization, metabolic deregulation, evasion of 
the immune system, and inflammation [37, 38].
It is by now a well-established concept that cancer 
cells not only possess cell autonomous mechanisms 
acquired by genetic mutations that convey some of these 
traits, but that their interaction with the local environ-
ment and even the whole organism may also play an 
important role in this. The tumor microenvironment 
that surrounds expanding cancer cells with immediate 
contact – also termed “stroma” – is believed to mainly 
function as a pool of resident and recruited “normal” cells 
that then become conscripted and corrupted by cancer 
cells to aid in the formation of an organ-like macroscopic 
tumor [39]. These cells can be categorized as infiltrating 
immune cells, cancer-associated fibroblasts (CAFs), and 
angiogenic vascular cells (AVCs; endothelial cells and 
pericytes) [40]. Although some aspects of the tumor-cell-
to-stroma interaction touching the hallmarks of cancer 
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(i.e. tumor angiogenesis and remodeling of the extracel-
lular matrix) have been thoroughly studied in the last 
decades [41, 42], the constituents of the stromal compart-
ment appear to elicit a vast but yet to be fully understood 
impact on cancer cells that may both permit and inhibit 
cancer growth. Although recent studies [43, 44] raised 
doubt (at least in the case of pancreatic carcinoma) about 
the prevailing conception that the tumor stroma elicits 
mainly tumor-supporting effects, a tumor- promoting 
influence of stromal cells has been demonstrated for all 
hallmarks of cancer, except for the capability of limitless 
replication of cancer cells [39]. Although the contribu-
tion of some stromal cell types to certain hallmarks may 
be self-evident (i.e. for endothelial cells to contribute to 
angiogenesis), the influence of stromal cells on cancer 
hallmarks appears to be much broader, mainly through 
paracrine and juxtacrine mitogens produced by these 
stromal cells [39].
MSCs contribute to the stroma
Both experimental and clinical studies have supplied 
convincing evidence supporting the theory that MSCs 
contribute to the cancer stroma. Expanding tumors con-
stantly alter their surrounding tissue causing an inflam-
matory response, which resembles that of a chronic 
wound [45]. Although MSCs physiologically have the 
capacity to become recruited to the sites of injury, they 
show a similar behavior (potentially by the same mech-
anisms) in the setting of a growing tumor [46]. In an 
animal model of melanoma, Studeny et al. were the first 
to describe the homing of labeled MSCs within the tumor 
stroma both after subcutaneous coinjection with tumor 
cells and after intravenous administration [47]. Biolumi-
nescence imaging allows for the longitudinal monitoring 
of systemically injected, labeled MSCs. Using this tech-
nique, Kidd et al. delivered a detailed information about 
the spatial distribution of MSCs after tail vein injection in 
mice with different conditions [20]. In mice bearing sub-
cutaneous breast cancers, MSCs were detectable in the 
lung capillaries during the first 6 days after injection but 
then colocalized with the growing tumors followed by 
cell proliferation in the subsequent 6 days. The homing 
of MSCs to the tumor stroma has been demonstrated for 
several other tumor entities besides breast cancer and 
melanoma including pancreatic [48], ovarian [49], pros-
tate [50], gastric [51], and hepatocellular carcinoma (HCC) 
[52] as well as glioma [53].
Although not fully understood, the process of MSC 
homing to tumors is believed to be a multistep process 
with similarities to that observed in leukocyte traffick-
ing. In the first step, in the case of endogenous MSCs, 
these are mobilized from the bone marrow and enter 
the circulation after chemotactic stimuli [54]. MSCs 
must then interact with the endothelium of the target 
tissue and adhere, extravasate, and engraft at sites of 
tumor. Several of these steps appear to be orchestrated 
by cytokines and chemokines. The adhesion of MSC to 
the endothelium, for example, is enhanced by the acti-
vation of the latter with the proinflammatory cytokine 
tumor necrosis factor-α (TNF-α) [55]. The chemokine 
(C-X-C motif) ligand 12 (CXCL12) is expressed in tissues 
after injury and hypoxia in a hypoxia-inducible factor-1 
(HIF-1)-dependent manner [56]. The chemokine axis of 
CXCL12/stromal cell-derived factor-1 (SDF-1) and CXCR4 
plays a pivotal role in both HSC homing and tumor cell 
metastasization to the bone marrow [57, 58]. Recent find-
ings also indicate the significance of CXCR4 signaling 
through both CXCL12 and macrophage migration inhibi-
tory factor (MIF) signaling for MSC homing to tumors 
[59, 60]. Although the reports in the literature differ in 
the expression levels of CXCR4 on MSCs, it appears that 
CXCR4 in nonactivated MSCs is expressed at a low level 
on the cell surface and at a high level in the intracellular 
compartment. It has been hypothesized, however, that 
MSCs – upon activation – are capable of quickly translo-
cating CXCR4 molecules to the cell surface, which then 
enables MSCs to follow CXCR4-mediated migration cues 
toward tumors [51, 61].
Function of MSCs in tumors
Although there are some reports on the tumor-suppressing 
effects of native MSCs (e.g. [62]), the overwhelming major-
ity of articles on this topic report the enhancing effects on 
nearly all aspects of malignant tumor growth [63]. Cuiffo 
and Karnoub described four general functional categories 
by which MSCs within the tumor stroma may influence 
tumor growth [63]: (1) through direct actions on tumor 
cells, (2) through indirect effects; such as the enhance-
ment of angiogenesis; (3) through their immunosuppres-
sive properties; and (4) as progenitors for tumor stromal 
cells.
First, MSCs seem to be capable of exerting a direct 
paracrine effect on cancer cells, resulting in the pro-
motion of tumor proliferation, invasion, and metasta-
sis.  Specifically, this has been shown for chemokines, 
cytokines, and growth factors released by MSCs. For 
example, MSC-derived CXCL1/2 and CXCL12/SDF-1 
enhance cancer cell proliferation through signaling on 
Bereitgestellt von | Ludwig-Maximilians-Universität München Universitätsbibliothek (LMU)
Angemeldet
Heruntergeladen am | 05.12.18 19:05
Niess et al.: Genetic engineering of MSCs for cancer therapy      23
their respective CXCR2 and CXCR4 receptors expressed 
by cancer cells [64, 65], IL-6 and IL-8 released by MSCs 
enhance malignancy in breast and colorectal cancer 
models [66, 67], and epidermal growth factor (EGF) 
secreted by MSCs enhances tumorigenesis in a breast 
cancer model [68]. The secretion of bioactive molecules 
by MSCs appears to happen as a context-dependent 
response upon interaction with certain cancer microen-
vironments. Whereas, for example, breast and pancre-
atic cancer cells were capable of inducing high levels of 
CCL5 secretion from MSCs, which in turn led to enhanced 
tumor growth and metastasization, other cancer cell lines 
did not provoke CCL5 secretion to increase [48, 69]. Fur-
thermore, MSCs appear to be capable of regulating and 
supporting cancer stem cells (CSC) in a similar fashion 
as within their physiological function with HSCs in the 
bone marrow. In the tumor stroma of breast cancer, MSCs 
augment the population of cancer cells that show CSC 
characteristics by paracrine secretion of IL-6 and CXCL7 
after homing to tumor sites [67]. Similar results were 
observed in a model of ovarian cancer, where MSCs raised 
the CSC count through BMP2 signaling [70]. To add to 
the tumor beneficial effects elicited by MSCs directly on 
cancer cells, MSCs have been shown to convey chemore-
sistance by releasing chemoprotective polyunsaturated 
fatty acids upon treatment with a platinum analog [71].
Second, MSCs within the tumor stroma may indirectly 
promote tumor growth by aiding in the process of tumor 
angiogenesis. Specifically, MSCs may do so by recruitment 
of endothelial progenitor cells and by enabling the forma-
tion and maturation of tumor vasculature [72, 73]. Their 
capacity to enhance angiogenesis was demonstrated in 
both wound healing and tumor models and conveyed by 
the secretion of proangiogenic factors such as vascular 
endothelial growth factor (VEGF), angiopoietins, and EGF 
[74, 75].
Third, MSCs within the tumor stroma may exer-
cise direct or indirect immunomodulatory effects that 
defend tumor cells from both adaptive and innate 
immune systems, as described earlier in this review. 
Although not necessarily based on cancer models, it has 
been proven that MSCs are capable of influencing the 
vast majority of key immune activities involved in the 
process of tumor formation. The immunosuppressive 
effects of MSCs are so profound that it appears that they 
are unmatched by other cell types of the tumor stroma, 
thus making MSCs a central element in the immunoeva-
siveness of tumors [63].
Fourth, MSCs may participate in the tumor microen-
vironment by providing a cell pool that forms the basis 
for several specialized stromal cells. Within the tumor 
stroma, MSCs not only influence cancer cells through 
paracrine signaling but also are themselves subjected to 
an array of signaling molecules, which in turn may result 
in the differentiation of MSCs toward a more special-
ized cell phenotype. The transdifferentiation of MSCs to 
CAFs and myofibroblasts, which in turn promote tumor 
growth, was demonstrated after signaling from tumor-
conditioned medium [76], tumor-derived exosomes [77], 
and xenografts from breast, pancreatic, and ovarian 
cancers [78] as well as prostate cancer [50]. Interest-
ingly, using an inflammation-induced gastric cancer 
model, Quante et al. were able to demonstrate that the 
process of MSC homing and differentiation toward CAFs 
is a process occurring early in the phase of dysplasia 
and tumor niche formation and is of utter importance 
to drive carcinogenesis [51]. In a prostate cancer model, 
the signaling of CXCL16 from the tumor microenviron-
ment on the CXCR6 receptor of MSCs seems to be of great 
importance for the differentiation of MSCs toward CAFs 
to occur [50].
Engineered MSCs for cancer therapy
The MSC traits of tumor tropism, deep migration into the 
tumor microenvironment, immune evasion, and wide 
availability as well as expandability have evoked a sub-
stantial interest in their use as tumor-specific vehicles for 
the delivery of therapeutic agents. Figure 1 provides an 
overview of the most commonly used strategies to geneti-
cally engineer MSCs to target tumors, which are discussed 
in this section.
Studeny et  al. used engineered MSCs with forced 
expression of IFN-β, a cytokine that conveys strong anti-
proliferative effects on several cell types, including tumor 
cells, and demonstrated the inhibited growth of metastatic 
melanoma. Here, the MSC-based delivery of IFN-β proved 
more capable of tumor inhibition compared to systemic 
IFN-β therapy [47]. Considering the existing evidence of 
the tumor-promoting properties of MSCs, however, an 
ideal setup would require MSCs containing antitumor 
therapeutics to stay viable until the delivery of the ther-
apeutic and then die immediately after the therapeutic 
effect has worn off to avoid tumor beneficial effects [79]. 
Whereas some MSC-based therapies, such as those using 
“suicide gene” strategies, bear this problem in mind, 
others do not and thus may potentially be too harmful to 
ever be used in a trial in human.
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Figure 1: Strategies for targeting MSCs against cancer.
Native MSCs, which are isolated and expanded from autologous or allogeneic donors, are consequently transfected with a therapeutic 
transgene. The most commonly used transgenes encode for either a “suicide gene” (A) or allow MSCs to secrete therapeutic proteins 
that either directly or indirectly affect tumor growth (B). (A) The “suicide gene” strategy foresees the insertion of a gene that enables the 
researcher to selectively target the transfected cells with a subsequently administered and otherwise nontoxic drug. When this drug is 
applied after homing of MSCs into the tumors, this strategy resembles that of a Trojan horse because, after the conversion/uptake of the 
then toxic drug, not only MSCs but also the surrounding tumor and stromal cells are killed (see Figure 2). These suicide genes can encode 
either for an enzyme (GDEPT; Figure 2) or for the NIS. (B) A wide range of genes encoding for therapeutic proteins have been transfected into 
MSCs and used to target different aspects of tumors. These can be divided into proteins that act directly on tumor cells and their receptors, 
such as TRAIL, IFN, and EGF, and proteins that indirectly affect tumor growth.
Engineered MSCs to modulate immune 
response
MSCs have been engineered to express and secrete high 
levels of cytokines with known antitumor activity into 
the microenvironment, with the aim to boost endoge-
nous immunity against cancer [47, 80]. A series of studies 
show that the tumor-promoting effects of MSCs through 
the suppression of the immune system can be overcome 
through genetic engineering of the cells to achieve the 
opposite. Both adaptive and innate immune systems 
have successfully been stimulated by genetically engi-
neered MSCs to inhibit tumor growth. The former, for 
example, has been achieved by MSCs expressing high 
levels of IL-2. This approach has yielded a prolonged 
survival of rats suffering from invasive glioma [81]. MSC-
based overexpression of IL-12, a cytokine with known 
effects on both T-cell and NK cell function, has been 
shown to inhibit the formation of lung metastasis and 
prolong the survival in several cancer models including 
renal cell carcinoma and glioma [82, 83]. These studies 
specifically emphasize the influence of MSC-derived 
IL-12 on the innate immune system, specifically on NK 
cells, as the former study was conducted in an animal 
model lacking an adaptive immune system and thus only 
influencing the innate immune system [83] and the latter 
study showing increased intratumoral NK cell count 
compared to T cells [82].
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Furthermore, MSCs overexpressing the chemokine 
CX3CL1 were shown to inhibit the formation of lung 
metastasis and prolong animal survival [84]. CX3CL1 
is an immunostimulatory molecule that is expressed 
on the cell surface but can also be shed into the extra-
cellular compartment. In its soluble form, it acts as a 
chemoattractant for T cells and monocytes, whereas its 
surface-bound version aids in the adhesion of leukocytes 
to activated endothelium [85]. However, it has also been 
shown that CX3CL1 enhances the attraction of CX3CR1-
expressing tumor cells to the bone with a concomitant 
formation of bone metastasis [85]. Thus, the expression of 
CX3CL1 appears to have site-dependent and tumor type-
dependent effects on cancer cell behavior and thus may 
not be regarded as the “golden bullet” against all types 
of cancer.
Delivery of cytotoxic agents and inhibitory 
molecules
MSCs have been genetically engineered to express mole-
cules with known apoptotic effects on tumor cells. Among 
these molecules, the cytokine TNF-α-related apoptosis-
inducing ligand (TRAIL) has shown very promising results. 
Although TRAIL induces apoptosis in tumor cells of numer-
ous entities through signaling on the TRAIL receptors 
DR4 and DR5, these receptors are not expressed in most 
normal tissues [86]. The systemic administration of recom-
binant TRAIL protein or agonistic antibodies to the TRAIL 
receptor has shown only moderate therapeutic efficacy in 
clinical trials [87, 88]. This is mainly due to the insufficient 
bioavailability of these proteins at the tumor site [89]. To 
overcome this, MSCs have been engineered to constitu-
tively express TRAIL and its soluble variant sTRAIL. This 
approach resulted in significantly inhibited tumor growth 
in models of colorectal [90], pancreatic [91], and hepato-
cellular [92] carcinoma as well as mesothelioma [93].
Another example of the efficacy of inhibitory mol-
ecules expressed by engineered MSCs to inhibit cancer 
growth is that of NK4, which acts as an antagonist of HGF. 
In an animal model of gastric cancer, MSC-derived NK4 
expression within the tumor leads to both increased tumor 
cell apoptosis and lower microvessel density, indicative of 
the inhibition of tumor angiogenesis [94].
“Suicide gene” therapy and prodrugs
Gene-directed enzyme-producing therapy (GDEPT) 
makes use of enzymes that are capable of metabolizing 
an otherwise harmless prodrug into a toxic metabolite 
and that are normally not present at a relevant concen-
tration in healthy human cells. Gene vectors encoding 
for such foreign, prodrug-converting enzymes are termed 
“suicide genes” and can be stably transfected into MSCs 
and thereby be targeted into tumors (Figure 2). After the 
expression of the GDEPT enzymes by MSCs inside the 
tumor, the systemic delivery of the nontoxic prodrug can 
result in a localized antitumor effect after the conversion 
of the prodrug. Toxic metabolites can then cause the death 
of the delivering MSC, which prevents any concomitant 
tumor-promoting effects of the MSC [95]. Furthermore, 
due to the prodrug’s increased bioavailability, perme-
ability, and increased half-life compared to conventional 
chemotherapy, these metabolites can diffuse, be actively 
transported to surrounding cells through gap junctions, 
or be taken up by phagocytosis [96]. This “bystander 
effect” results in the death of neighboring tumor and 
stromal cells.
The two GDEPT strategies that have been most fre-
quently deployed to MSCs include herpes simplex virus-
thymidine kinase (HSV-Tk) with ganciclovir (GCV) as the 
prodrug and cytosine deaminase (CD) with 5-fluorocyto-
sine (5-FC) as the prodrug (reviewed in [97]).
In cells expressing HSV-Tk, the prodrug GCV is phos-
phorylated by the enzyme into a monophosphate form, 
which then is converted to GCV biphosphate and triphos-
phate by endogenous kinases. GCV triphosphate effec-
tively inhibits DNA synthesis and consequently leads 
to cell death after cell cycle arrest [97]. In this model of 
GDEPT, the bystander killing effect is highly dependent on 
gap junctions and phagocytosis of the active metabolite 
after cell death, as GCV triphosphate is unable to passively 
permeate cell membranes [96, 98]. The tumor-killing 
effects of HSV-Tk-transfected MSCs in combination with 
GCV has been shown in tumor models of glioma. Miletic 
et  al. showed that the injection of HSV-Tk-expressing 
MSCs in the vicinity or inside the tumor followed by the 
systemic administration of GCV inhibited tumor growth 
[99]. To enhance the efficacy of GDEPT, MSCs coexpress-
ing HSV-Tk and TRAIL were tested in tumor models. The 
application of these cells resulted in beneficial effects in 
animal models of glioblastoma and renal cell carcinoma 
[95, 100].
Similar effects were achieved using MSCs that were 
transfected with CD as suicide gene, which is capable 
of metabolizing 5-FC to its toxic form 5-fluorouracil 
(5-FU). 5-FU is a commonly used chemotherapeutic 
agent for the treatment of several tumor entities, but 
 chemoresistance against 5-FU is frequently observed. 
However, using the prodrug/suicide gene strategy, 
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Figure 2: Constitutive vs. tumor-specific expression of suicide genes.
(A) When using a gene vector, in which suicide gene expression is driven by a constitutively activated promoter (e.g. the CMV promoter), 
all MSCs express this gene regardless of their surrounding environment. When systemically injected into tumor-bearing mice, the tumor 
tropism of MSCs will lead to the preferential homing of MSCs into the tumor in which they can be targeted by prodrug administration (C). 
However, not all MSCs home into the tumor. A majority of suicide gene-expressing cells will reside in healthy organs, such as the lungs and 
spleen, thereby potentially causing off-target toxicity. (B) In an attempt to further enhance the tumor specificity of therapy, the expression of 
suicide genes has been put under the control of promoters that are suspected to become activated specifically after the homing of MSCs to 
tumors. These promoters include the Tie-2 promoter and the CCL5/RANTES promoter. In this setting, MSCs only express the suicide gene fol-
lowing the respective stimuli from the tumor microenvironment and thereby MSCs that did not home into the tumor but into healthy organs 
do not express the suicide gene. This approach is believed to raise the amount of GDEPT enzymes within the tumor and limit off-target 
toxicity. (C) The mechanism of cell killing is the same for both strategies. After the systemic injection of an otherwise nontoxic prodrug, it 
becomes converted into the active drug only in cells that express the respective enzyme. Via the bystander effect, the toxin is distributed to 
the surrounding cells, which leads to subsequent cell killing.
much higher levels of 5-FU can be achieved within the 
tumor compared to the systemic infusion of 5-FU while 
off-target  concentration and thus toxicity are limited 
[101]. Furthermore, the easy diffusion of 5-FU through 
cell membranes  independently of gap junctions yields 
a greater bystander effect of the CD/5-FU system com-
pared to other GDEPT  strategies [97]. The therapeutic 
efficacy of MSCs transfected with CD  followed by 5-FC 
application has been shown in animal models of colon 
cancer [101], osteosarcoma [102], glioma [103], and pros-
tate cancer [104].
Tumor-specific transgene expression
The lack of tumor specificity of systemically applied 
conventional cancer treatment agents – which results in 
insufficient concentration of the agent in tumor cells and 
toxic effects in normal cells – is one of the major obsta-
cles faced in cancer treatment (see Figure 2). Although 
all therapeutic strategies outlined above make use of the 
innate capability of MSCs to home to growing tumors and 
by this comprise a tactic to increase the tumor specific-
ity of systemically applied therapy, this homing process 
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is not exclusive to tumors. After injection, MSCs can also 
be found in large number in otherwise healthy tissues, 
presumably in the context of normal tissue homeostasis 
[105]. Whereas in all studies mentioned above the thera-
peutic transgene is expressed constitutively, thus pos-
sibly still causing off-target toxicity, several groups have 
developed gene vectors where the therapeutic transgene 
is driven under the control of gene promoters that are acti-
vated after the homing of MSCs to tumors, with the aim 
to further increase tumor specificity. The promoters con-
trolling suicide gene expression were selected according 
to the known functions of MSCs after homing to the tumor 
and that are outlined above [106]. Because these signal-
ing processes occur after MSC homing and within the 
tumor microenvironment, they can be regarded as tumor- 
specific  triggers for gene expression.
Tie-2, a cell surface receptor for the proangiogenic 
factor angiopoietin-1, is expressed mainly on endothe-
lial cells and pericytes, in which MSCs can act as a pre-
cursor cell for both [74, 107–109]. MSCs transfected with 
HSV-Tk as a suicide gene, whose expression is put under 
the control of the Tie-2 promoter/enhancer, express this 
therapeutic gene after homing to pancreatic, breast, and 
liver cancers in respective animal models [52, 110]. The 
treatment of these animals with GCV injections resulted in 
reduced tumor growth and prolonged survival with little 
off-target gene expression.
Karnoub et  al. previously demonstrated the strong 
expression of CCL5/RANTES after homing to breast cancer 
xenografts, a process believed to occur as part of the dif-
ferentiation process of MSCs to CAFs [69]. This process 
requires the immediacy of MSCs to tumor cells, which 
in turn is a prerequisite for achieving tumor-specific 
transgene expression. Using the CCL5/RANTES promoter 
to control HSV-Tk expression in MSCs resulted in strong 
expression of the suicide gene in orthotopic animal 
models for pancreatic and liver cancers [48, 52]. The treat-
ment with GCV significantly reduced tumor growth in both 
models as well as reduced peritoneal and liver metastasis 
in the latter model.
Yan et  al. evaluated the promoter region of 
α-fetoprotein (AFP) as a regulator for tumor-specific 
sTRAIL expression by MSCs in an animal model of HCC 
[111]. After the injection of MSCs transfected with a gene 
vector, in which sTRAIL is expressed under the control of 
the AFP promoter, merely the hepatic tumor environment 
appears to elicit the activation stimuli of the AFP promoter 
in MSCs, as the authors were able to find sTRAIL expres-
sion only within the tumors. This therapy was potent 
enough to significantly inhibit tumor growth.
“Theranostic” sodium/iodide symporter 
(NIS) for tumor-specific MSC therapy
NIS is normally expressed on the surface of thyroid folli-
cular cells and facilitates the transport of iodide into the 
cell [112]. Its physiological occurrence is highly specific 
for the thyroid gland and its expression is mandatory 
for radioiodine therapy to be effective but can also serve 
diagnostic purposes using 99mTc- or 123I-scintigraphy/sin-
gle-photon emission computed tomography (SPECT) as 
well as 124I- or 18F-TFB-PET imaging. Engineering other-
wise NIS-negative cells to express NIS is thus an elegant 
method to both make these cells susceptible to targeted 
therapy and track them in vivo by aforementioned 
imaging strategies. Radioiodine therapy with 131I is a 
well-established and very effective therapy for thyroid 
cancer and involves a profound bystander effect, as the 
path length of this β-emitter is 2.4 mm, thus also subject-
ing immediately surrounding tumor and stromal cells to 
radiation [113].
MSCs engineered for constitutive NIS expression were 
tracked over 2 weeks in an animal model of breast cancer 
using 99mTc SPECT imaging. On day 14 after injection, 
NIS expression within the tumor had visibly increased, 
whereas in nontarget tissues NIS expression had signifi-
cantly decreased compared to the early phase after injec-
tion [114]. The MSC-based mediation of NIS expression 
within the tumors resulted in their susceptibility to radi-
oiodine therapy, which caused a significant inhibition of 
tumor growth. Similar results were obtained in an animal 
model of HCC, where NIS-transfected MSCs triggered the 
proneness of HCC cells to 131I therapy both in vitro and 
in vivo [115].
Using the same animal model, the tumor microenvi-
ronment-dependent expression of NIS was successfully 
achieved using the CCL5/RANTES promoter to trigger 
NIS expression in MSCs. After the injection of cells, the 
group observed a tumor-selective radionuclide accumu-
lation in scintigraphy and high efficacy of the concomi-
tant radioiodine therapy [116]. Furthermore, by means 
of the same RANTES/NIS-transfected MSC cell line, the 
same group was even capable of targeting liver metasta-
ses from colon cancer in a respective animal model [117]. 
This intriguing study (1) demonstrates that MSC-based 
gene therapy may be an effective method not only for 
primary tumors but also for metastatic disease and (2) 
opens up the prospect of using genetically engineered 
MSCs as a diagnostic tool to render micrometastasis, 
which are otherwise invisible to conventional imaging, 
visible, for example, to SPECT.
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Clinical studies using MSC for cancer therapy
We initiated a phase I/II clinical study in which autolo-
gous MSCs from patients suffering from advanced, recur-
rent, or metastatic adenocarcinoma of the gastrointestinal 
or hepatopancreatobiliary system are used to deliver a 
GDEPT [118]. After isolation from a bone marrow aspirate 
from each study participant, MSCs were transfected with 
a gene vector that contained the CCL5/RANTES promoter 
to control HSV-Tk expression. Patients received three treat-
ment cycles, with each consisting of one injection of MSCs 
followed by 3 days of GCV injection starting 48 h after MSC 
infusion. The aims of the study were to determine the safety 
and feasibility of the therapy in humans, to detect possible 
side effects, and to find the optimal dosage of cells.
Another phase I study on genetically engineered 
MSCs for cancer therapy is currently being prepared at 
the MD Anderson Cancer Center. The published study 
protocol (ClinicalTrials.gov number NCT02530047) fore-
sees the use of MSCs isolated from healthy donors and 
genetically modified to express IFN-β. These cells are then 
administered intraperitoneally in patients suffering from 
advanced ovarian cancer. The study is scheduled to start 
recruiting in August 2016.
In an attempt to deliver oncolytic viruses to recurrent 
ovarian cancers, a research group from the Mayo Clinic 
has initiated a phase I/II clinical trial in which adipose 
tissue-derived MSCs are used as cellular vehicles for the 
delivery of NIS-expressing measles viruses (ClinicalTri-
als.gov number NCT02068794). The success rate of virus 
spread to the tumor can then be monitored using the NIS 
system in SPECT imaging.
Conclusion and perspective
MSCs are multipotent adult cells with diverse biological 
functions. Among other functions, MSCs contribute to 
tissue regeneration; thus, MSCs have become an intensely 
studied cell population for strategies to improve this 
process. However, MSCs are also encroached by growing 
tumors to aid in the formation of tumor stroma, thus exert-
ing a multitude of effects on cancer growth. Our growing 
knowledge about the mechanisms of this phenomenon 
allows us to use MSCs as delivery vehicles for cancer 
therapeutics. Genetic engineering with tissue-dependent 
expression of therapeutic transgenes further increases 
the tumor specificity of this therapy. Although the first 
clinical studies have been initiated just recently, there is 
still a wide range of unanswered questions but also possi-
bilities for the optimization of this therapeutic approach. 
The most pressing issues in this regard are the following: 
Which tissue source should be used for MSC isolation? 
Which therapeutic construct is most effective for which 
tumor type? Which administration route is ideal? Which 
strategy of genetic engineering yields the most stable 
transgene expression but is still safe to use in humans? 
Will the best results be achieved with MSCs from young, 
healthy donors, which may have the benefits of being 
more easily expandable and transfectable in culture and 
possibly also show more profound tumor homing and 
transdifferentiation, or does the problem of rejection that 
possibly occurs during an allogeneic MSC infusion out-
weigh these benefits? By which strategy can the tumor 
beneficial effects of exogenously applied MSCs be coun-
teracted? How can we enhance the number of MSCs actu-
ally homing to the tumor? Furthermore, a more profound 
knowledge about the molecular mechanisms of endog-
enous MSC mobilization, homing, and differentiation and 
how to abrogate each one of these steps could potentially 
yield an effective anticancer therapy in itself.
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